For research use only. Not for therapeutic Use.
Orally potent and selective dual PI3K/mTOR inhibitor; IC50 values to be 72, 2336, 201 and 382 nM for PI3K p110 α, β, δ and γ isoforms, respectively; inhibition of PI3K/mTOR pathway like NVP-BEZ235, BBD130 efficiently attenuates growth and proliferation of melanoma primary tumors and metastasis
| Catalog Number | I047543 |
| CAS Number | 853910-61-9 |
| Molecular Formula | C28H21N5O |
| Purity | ≥95% |
| IUPAC Name | 2-methyl-2-[4-[3-methyl-2-oxo-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile |
| InChI | InChI=1S/C28H21N5O/c1-28(2,18-29)21-9-11-22(12-10-21)33-26-23-15-19(6-7-20-5-4-14-30-16-20)8-13-24(23)31-17-25(26)32(3)27(33)34/h4-5,8-17H,1-3H3 |
| SMILES | CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C#CC5=CN=CC=C5 |
| Reference | R Marone et al. Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. Mol. Cancer Res. 2009, 7(4), 601-613.
F Stauffer et al. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett. 2008, 18, 1027-1030.
SM Maria, P Furet and F Stauffer. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Future Med. Chem. 2009, 1(1), 137-155. |
